

Advanced Prostate Cancer

Treatment approaches covered

Hormonal therapy | Chemotherapy | Immunotherapy | Radiopharmaceuticals | Radiation
Interventions for complications of local progression



Details

- 1 Recorded via the Common Terminology Criteria for Adverse Events (CTCAE), version 4.0
- 2 Recorded via the Eastern Cooperative Oncology Group (ECOG) score
- 3 Includes pain-related quality of life and need for pain medication
- 4 Includes urinary incontinence, urinary frequency, urinary obstruction, urinary irritation, and bowel irritation
- 5 Includes hormonal symptoms

- 6 Recommended to track via the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)
- 7 Recommended to track via the Expanded Prostate Cancer Index Composite (EPIC 26 version preferred)
- 8 Includes symptomatic skeletal related event, time to metastasis, castration resistant disease, and procedures needed for local progression

For a complete overview of this Set, including definitions for each measure, time points for collection, and associated risk factors, visit <https://connect.ichom.org/patient-centered-outcome-measures/advanced-prostate-cancer/>

Contributors

For more information about the process of developing a Set of Patient-Centered Outcome Measures, visit ichom.org/how-we-work/

The Sponsor



The Working Group



Australia

Ian Davis | Monash University; Eastern Health Clinical School
Sue Evans | Monash University
Ian Roos* | Cancer Action Victoria

Belgium

Louis Denis* | Oncology Center Antwerp, US TOO Belgium
Bertrand Tombal | Cliniques Universitaires Saint Luc, Université Catholique de Louvain

Canada

Neil Fleshner | University of Toronto
Andrew Matthew | University of Toronto

France

Alberto Bossi | Gustave Roussy Cancer Institute

Germany

Thomas Steuber | University Hospital Hamburg-Eppendorf

Ireland

Ray McDermott | St. Vincent's University Hospital

Netherlands

Theo de Reijke | Academic Medical Center Amsterdam

Jean-Paul van Basten | Canisius Wilhelmina Hospital

Koos van der Hoeven | Leiden University Medical Center

United Kingdom

Heather Payne | University College Hospitals London

United States

Janet Abraham | Dana-Farber Cancer Institute

Ethan Basch | University of North Carolina at Chapel Hill

Justin Bekelman | University of Pennsylvania

Donna Berry | Dana-Farber Cancer Institute

Daniel George | Duke University Medical Center

Jim Kiefert* | US TOO

Daniel Lin | University of Washington
Alicia Morgans | Vanderbilt University Medical Center

David Penson | Vanderbilt University Medical Center

Deborah Schrag | Dana-Farber Cancer Institute

*Patient representative